Longitudinal study of beta2-microglobulin abnormalities in schizophrenia.
In an earlier cross-sectional study, we reported antipsychotic-naive schizophrenia patients to have significantly elevated beta2-microglobulin (beta2M) level suggestive of its potential association with the pathogenesis of schizophrenia. In this study, we present the follow-up analyses of beta2M in 31 patients from the previous study who were re-assessed after 92.1+/-7.2 days of antipsychotic treatment. Compared to baseline, there was a further significant elevation of beta2M in schizophrenia patients following treatment, especially in those who were treated with risperidone. Also, there was a significant negative correlation between beta2M level and total psychopathology score during follow-up in risperidone group. The study findings extend further support the role for beta2M in the pathogenesis of schizophrenia strengthening the case for immune dysregulation. Moreover, the observations suggest the possibility that the mechanism of action of antipsychotics might involve alteration of immune parameters.
Chittiprol
Seetharamaiah
S
Department of Neurochemistry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Venkatasubramanian
Ganesan
G
Neelakantachar
Narendran
N
Reddy
Naveen A
NA
Shetty
Kurudunje Taranath
KT
Gangadhar
Bangalore N
BN
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007107:Immune System / Q000187:drug effects; D008297:Male; D015213:Neuroimmunomodulation; D018967:Risperidone / Q000008:administration & dosage; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D001613:beta 2-Microglobulin / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics
D014150:Antipsychotic Agents; D001613:beta 2-Microglobulin; D018967:Risperidone